TY - JOUR AU - Ben-David, U. AU - Beroukhim, R. AU - Golub, T. R. PY - 2019 DA - 2019// TI - Genomic evolution of cancer models: perils and opportunities JO - Nat Rev Cancer VL - 19 UR - https://doi.org/10.1038/s41568-018-0095-3 DO - 10.1038/s41568-018-0095-3 ID - Ben-David2019 ER - TY - JOUR AU - Kalimutho, M. AU - Nones, K. AU - Srihari, S. PY - 2019 DA - 2019// TI - Patterns of genomic instability in breast cancer JO - Trends Pharmacol Sci VL - 40 UR - https://doi.org/10.1016/j.tips.2019.01.005 DO - 10.1016/j.tips.2019.01.005 ID - Kalimutho2019 ER - TY - JOUR AU - Yi, M. AU - Qin, S. AU - Zhao, W. PY - 2018 DA - 2018// TI - The role of neoantigen in immune checkpoint blockade therapy JO - Exp Hematol Oncol. VL - 7 UR - https://doi.org/10.1186/s40164-018-0120-y DO - 10.1186/s40164-018-0120-y ID - Yi2018 ER - TY - JOUR AU - Marin-Acevedo, J. A. AU - Soyano, A. E. AU - Dholaria, B. AU - Knutson, K. L. AU - Lou, Y. PY - 2018 DA - 2018// TI - Cancer immunotherapy beyond immune checkpoint inhibitors JO - J Hematol Oncol. VL - 11 UR - https://doi.org/10.1186/s13045-017-0552-6 DO - 10.1186/s13045-017-0552-6 ID - Marin-Acevedo2018 ER - TY - JOUR AU - Motegi, A. AU - Masutani, M. AU - Yoshioka, K. I. AU - Bessho, T. PY - 2019 DA - 2019// TI - Aberrations in DNA repair pathways in cancer and therapeutic significances JO - Semin Cancer Biol VL - 58 UR - https://doi.org/10.1016/j.semcancer.2019.02.005 DO - 10.1016/j.semcancer.2019.02.005 ID - Motegi2019 ER - TY - JOUR AU - Hu, H. AU - Li, H. AU - Jiao, F. PY - 2017 DA - 2017// TI - Association of a novel point mutation in MSH2 gene with familial multiple primary cancers JO - J Hematol Oncol. VL - 10 UR - https://doi.org/10.1186/s13045-017-0523-y DO - 10.1186/s13045-017-0523-y ID - Hu2017 ER - TY - JOUR AU - Lord, C. J. AU - Tutt, A. N. AU - Ashworth, A. PY - 2015 DA - 2015// TI - Synthetic lethality and cancer therapy: lessons learned from the development of PARP inhibitors JO - Annu Rev Med VL - 66 UR - https://doi.org/10.1146/annurev-med-050913-022545 DO - 10.1146/annurev-med-050913-022545 ID - Lord2015 ER - TY - JOUR AU - Hu, X. AU - Huang, W. AU - Fan, M. PY - 2017 DA - 2017// TI - Emerging therapies for breast cancer JO - J Hematol Oncol. VL - 10 UR - https://doi.org/10.1186/s13045-017-0466-3 DO - 10.1186/s13045-017-0466-3 ID - Hu2017 ER - TY - JOUR AU - George, A. AU - Kaye, S. AU - Banerjee, S. PY - 2017 DA - 2017// TI - Delivering widespread BRCA testing and PARP inhibition to patients with ovarian cancer JO - Nat Rev Clin Oncol. VL - 14 UR - https://doi.org/10.1038/nrclinonc.2016.191 DO - 10.1038/nrclinonc.2016.191 ID - George2017 ER - TY - JOUR AU - Jalal, S. AU - Earley, J. N. AU - Turchi, J. J. PY - 2011 DA - 2011// TI - DNA repair: from genome maintenance to biomarker and therapeutic target JO - Clin Cancer Res VL - 17 UR - https://doi.org/10.1158/1078-0432.CCR-11-0761 DO - 10.1158/1078-0432.CCR-11-0761 ID - Jalal2011 ER - TY - JOUR AU - Ghelli Luserna Rora, A. AU - Iacobucci, I. AU - Martinelli, G. PY - 2017 DA - 2017// TI - The cell cycle checkpoint inhibitors in the treatment of leukemias JO - J Hematol Oncol. VL - 10 UR - https://doi.org/10.1186/s13045-017-0443-x DO - 10.1186/s13045-017-0443-x ID - Ghelli Luserna Rora2017 ER - TY - JOUR AU - Germano, G. AU - Amirouchene-Angelozzi, N. AU - Rospo, G. AU - Bardelli, A. PY - 2018 DA - 2018// TI - The clinical impact of the genomic landscape of mismatch repair-deficient cancers JO - Cancer Discov VL - 8 UR - https://doi.org/10.1158/2159-8290.CD-18-0150 DO - 10.1158/2159-8290.CD-18-0150 ID - Germano2018 ER - TY - JOUR AU - Zhu, J. AU - Jia, W. AU - Wu, C. PY - 2018 DA - 2018// TI - Base excision repair gene polymorphisms and wilms tumor susceptibility JO - EBioMedicine. VL - 33 UR - https://doi.org/10.1016/j.ebiom.2018.06.018 DO - 10.1016/j.ebiom.2018.06.018 ID - Zhu2018 ER - TY - JOUR AU - Amir, E. AU - Seruga, B. AU - Serrano, R. AU - Ocana, A. PY - 2010 DA - 2010// TI - Targeting DNA repair in breast cancer: a clinical and translational update JO - Cancer Treat Rev VL - 36 UR - https://doi.org/10.1016/j.ctrv.2010.03.006 DO - 10.1016/j.ctrv.2010.03.006 ID - Amir2010 ER - TY - JOUR AU - Pilie, P. G. AU - Gay, C. M. AU - Byers, L. A. AU - O’Connor, M. J. AU - Yap, T. A. PY - 2019 DA - 2019// TI - PARP inhibitors: extending benefit beyond BRCA-Mutant cancers JO - Clin Cancer Res VL - 25 UR - https://doi.org/10.1158/1078-0432.CCR-18-0968 DO - 10.1158/1078-0432.CCR-18-0968 ID - Pilie2019 ER - TY - JOUR AU - Kaniecki, K. AU - Tullio, L. AU - Greene, E. C. PY - 2018 DA - 2018// TI - A change of view: homologous recombination at single-molecule resolution JO - Nat Rev Genet VL - 19 UR - https://doi.org/10.1038/nrg.2017.92 DO - 10.1038/nrg.2017.92 ID - Kaniecki2018 ER - TY - JOUR AU - Balmus, G. AU - Pilger, D. AU - Coates, J. PY - 2019 DA - 2019// TI - ATM orchestrates the DNA-damage response to counter toxic non-homologous end-joining at broken replication forks JO - Nat Commun. VL - 10 UR - https://doi.org/10.1038/s41467-018-07729-2 DO - 10.1038/s41467-018-07729-2 ID - Balmus2019 ER - TY - JOUR AU - Metzger, M. J. AU - Stoddard, B. L. AU - Monnat, R. J. PY - 2013 DA - 2013// TI - PARP-mediated repair, homologous recombination, and back-up non-homologous end joining-like repair of single-strand nicks JO - DNA Repair VL - 12 UR - https://doi.org/10.1016/j.dnarep.2013.04.004 DO - 10.1016/j.dnarep.2013.04.004 ID - Metzger2013 ER - TY - JOUR AU - Aparicio, T. AU - Baer, R. AU - Gautier, J. PY - 2014 DA - 2014// TI - DNA double-strand break repair pathway choice and cancer JO - DNA Repair VL - 19 UR - https://doi.org/10.1016/j.dnarep.2014.03.014 DO - 10.1016/j.dnarep.2014.03.014 ID - Aparicio2014 ER - TY - JOUR AU - Mengwasser, K. E. AU - Adeyemi, R. O. AU - Leng, Y. PY - 2019 DA - 2019// TI - Genetic screens reveal FEN1 and APEX2 as BRCA2 synthetic lethal targets JO - Mol Cell VL - 73 ID - Mengwasser2019 ER - TY - JOUR AU - Groschel, S. AU - Hubschmann, D. AU - Raimondi, F. PY - 2019 DA - 2019// TI - Defective homologous recombination DNA repair as therapeutic target in advanced chordoma JO - Nat Commun. VL - 10 UR - https://doi.org/10.1038/s41467-019-09633-9 DO - 10.1038/s41467-019-09633-9 ID - Groschel2019 ER - TY - JOUR AU - Fong, P. C. AU - Boss, D. S. AU - Yap, T. A. PY - 2009 DA - 2009// TI - Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers JO - N Engl J Med VL - 361 UR - https://doi.org/10.1056/NEJMoa0900212 DO - 10.1056/NEJMoa0900212 ID - Fong2009 ER - TY - JOUR AU - Fong, P. C. AU - Yap, T. A. AU - Boss, D. S. PY - 2010 DA - 2010// TI - Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval JO - J Clin Oncol VL - 28 UR - https://doi.org/10.1200/JCO.2009.26.9589 DO - 10.1200/JCO.2009.26.9589 ID - Fong2010 ER - TY - JOUR AU - Mukhopadhyay, A. AU - Plummer, E. R. AU - Elattar, A. PY - 2012 DA - 2012// TI - Clinicopathological features of homologous recombination-deficient epithelial ovarian cancers: sensitivity to PARP inhibitors, platinum, and survival JO - Cancer Res VL - 72 UR - https://doi.org/10.1158/0008-5472.CAN-12-0324 DO - 10.1158/0008-5472.CAN-12-0324 ID - Mukhopadhyay2012 ER - TY - JOUR AU - Helleday, T. PY - 2011 DA - 2011// TI - The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings JO - Mol Oncol. VL - 5 UR - https://doi.org/10.1016/j.molonc.2011.07.001 DO - 10.1016/j.molonc.2011.07.001 ID - Helleday2011 ER - TY - JOUR AU - Murai, J. AU - Huang, S. Y. AU - Das, B. B. PY - 2012 DA - 2012// TI - Trapping of PARP1 and PARP2 by clinical PARP inhibitors JO - Cancer Res VL - 72 UR - https://doi.org/10.1158/0008-5472.CAN-12-2753 DO - 10.1158/0008-5472.CAN-12-2753 ID - Murai2012 ER - TY - JOUR AU - Farmer, H. AU - McCabe, N. AU - Lord, C. J. PY - 2005 DA - 2005// TI - Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy JO - Nature VL - 434 UR - https://doi.org/10.1038/nature03445 DO - 10.1038/nature03445 ID - Farmer2005 ER - TY - JOUR AU - Keung, M. Y. T. AU - Wu, Y. AU - Vadgama, J. V. PY - 2019 DA - 2019// TI - PARP inhibitors as a therapeutic agent for homologous recombination deficiency in breast cancers JO - J Clin Med. UR - https://doi.org/10.3390/jcm8040435 DO - 10.3390/jcm8040435 ID - Keung2019 ER - TY - JOUR AU - Faraoni, I. AU - Graziani, G. PY - 2018 DA - 2018// TI - Role of BRCA mutations in cancer treatment with poly(ADP-ribose) polymerase (PARP) inhibitors JO - Cancers (Basel). UR - https://doi.org/10.3390/cancers10120487 DO - 10.3390/cancers10120487 ID - Faraoni2018 ER - TY - JOUR AU - Krishnakumar, R. AU - Kraus, W. L. PY - 2010 DA - 2010// TI - The PARP side of the nucleus: molecular actions, physiological outcomes, and clinical targets JO - Mol Cell VL - 39 UR - https://doi.org/10.1016/j.molcel.2010.06.017 DO - 10.1016/j.molcel.2010.06.017 ID - Krishnakumar2010 ER - TY - JOUR AU - Murai, J. AU - Huang, S. Y. AU - Renaud, A. PY - 2014 DA - 2014// TI - Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib JO - Mol Cancer Ther VL - 13 UR - https://doi.org/10.1158/1535-7163.MCT-13-0803 DO - 10.1158/1535-7163.MCT-13-0803 ID - Murai2014 ER - TY - JOUR AU - Rouleau, M. AU - Patel, A. AU - Hendzel, M. J. AU - Kaufmann, S. H. AU - Poirier, G. G. PY - 2010 DA - 2010// TI - PARP inhibition: PARP1 and beyond JO - Nat Rev Cancer VL - 10 UR - https://doi.org/10.1038/nrc2812 DO - 10.1038/nrc2812 ID - Rouleau2010 ER - TY - JOUR AU - Schreiber, V. AU - Dantzer, F. AU - Ame, J. C. AU - Murcia, G. PY - 2006 DA - 2006// TI - Poly(ADP-ribose): novel functions for an old molecule JO - Nat Rev Mol Cell Biol VL - 7 UR - https://doi.org/10.1038/nrm1963 DO - 10.1038/nrm1963 ID - Schreiber2006 ER - TY - JOUR AU - Terada, M. AU - Fujiki, H. AU - Marks, P. A. AU - Sugimura, T. PY - 1979 DA - 1979// TI - Induction of erythroid differentiation of murine erythroleukemia cells by nicotinamide and related compounds JO - Proc Natl Acad Sci USA. VL - 76 UR - https://doi.org/10.1073/pnas.76.12.6411 DO - 10.1073/pnas.76.12.6411 ID - Terada1979 ER - TY - JOUR AU - Kaufman, B. AU - Shapira-Frommer, R. AU - Schmutzler, R. K. PY - 2015 DA - 2015// TI - Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation JO - J Clin Oncol VL - 33 UR - https://doi.org/10.1200/JCO.2014.56.2728 DO - 10.1200/JCO.2014.56.2728 ID - Kaufman2015 ER - TY - JOUR AU - Swisher, E. M. AU - Lin, K. K. AU - Oza, A. M. PY - 2017 DA - 2017// TI - Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial JO - Lancet Oncol. VL - 18 UR - https://doi.org/10.1016/S1470-2045(16)30559-9 DO - 10.1016/S1470-2045(16)30559-9 ID - Swisher2017 ER - TY - JOUR AU - Sandhu, S. K. AU - Schelman, W. R. AU - Wilding, G. PY - 2013 DA - 2013// TI - The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial JO - Lancet Oncol. VL - 14 UR - https://doi.org/10.1016/S1470-2045(13)70240-7 DO - 10.1016/S1470-2045(13)70240-7 ID - Sandhu2013 ER - TY - JOUR AU - Bono, J. AU - Ramanathan, R. K. AU - Mina, L. PY - 2017 DA - 2017// TI - Phase I, dose-escalation, two-part trial of the PARP inhibitor talazoparib in patients with advanced germline BRCA1/2 mutations and selected sporadic cancers JO - Cancer Discov VL - 7 UR - https://doi.org/10.1158/2159-8290.CD-16-1250 DO - 10.1158/2159-8290.CD-16-1250 ID - Bono2017 ER - TY - JOUR AU - Thomas, A. AU - Murai, J. AU - Pommier, Y. PY - 2018 DA - 2018// TI - The evolving landscape of predictive biomarkers of response to PARP inhibitors JO - J Clin Invest. VL - 128 UR - https://doi.org/10.1172/JCI120388 DO - 10.1172/JCI120388 ID - Thomas2018 ER - TY - JOUR AU - Lord, C. J. AU - Ashworth, A. PY - 2017 DA - 2017// TI - PARP inhibitors: Synthetic lethality in the clinic JO - Science VL - 355 UR - https://doi.org/10.1126/science.aam7344 DO - 10.1126/science.aam7344 ID - Lord2017 ER - TY - JOUR AU - Liu, F. W. AU - Tewari, K. S. PY - 2016 DA - 2016// TI - New targeted agents in gynecologic cancers: synthetic lethality, homologous recombination deficiency, and PARP inhibitors JO - Curr Treat Options Oncol VL - 17 UR - https://doi.org/10.1007/s11864-015-0378-9 DO - 10.1007/s11864-015-0378-9 ID - Liu2016 ER - TY - JOUR AU - Friedlander, M. AU - Gebski, V. AU - Gibbs, E. PY - 2018 DA - 2018// TI - Health-related quality of life and patient-centred outcomes with olaparib maintenance after chemotherapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT Ov-21): a placebo-controlled, phase 3 randomised trial JO - Lancet Oncol. VL - 19 UR - https://doi.org/10.1016/S1470-2045(18)30343-7 DO - 10.1016/S1470-2045(18)30343-7 ID - Friedlander2018 ER - TY - JOUR AU - Ledermann, J. A. AU - Harter, P. AU - Gourley, C. PY - 2016 DA - 2016// TI - Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial JO - Lancet Oncol. VL - 17 UR - https://doi.org/10.1016/S1470-2045(16)30376-X DO - 10.1016/S1470-2045(16)30376-X ID - Ledermann2016 ER - TY - JOUR AU - Robson, M. AU - Im, S. A. AU - Senkus, E. PY - 2017 DA - 2017// TI - Olaparib for metastatic breast cancer in patients with a germline BRCA mutation JO - N Engl J Med VL - 377 UR - https://doi.org/10.1056/NEJMoa1706450 DO - 10.1056/NEJMoa1706450 ID - Robson2017 ER - TY - JOUR AU - Golan, T. AU - Hammel, P. AU - Reni, M. PY - 2019 DA - 2019// TI - Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer JO - N Engl J Med VL - 381 UR - https://doi.org/10.1056/NEJMoa1903387 DO - 10.1056/NEJMoa1903387 ID - Golan2019 ER - TY - JOUR AU - Coleman, R. L. AU - Oza, A. M. AU - Lorusso, D. PY - 2017 DA - 2017// TI - Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial JO - Lancet VL - 390 UR - https://doi.org/10.1016/S0140-6736(17)32440-6 DO - 10.1016/S0140-6736(17)32440-6 ID - Coleman2017 ER - TY - JOUR AU - Pearre, D. C. AU - Tewari, K. S. PY - 2018 DA - 2018// TI - Targeted treatment of advanced ovarian cancer: spotlight on rucaparib JO - Ther Clin Risk Manag VL - 14 UR - https://doi.org/10.2147/TCRM.S149248 DO - 10.2147/TCRM.S149248 ID - Pearre2018 ER - TY - JOUR AU - Mirza, M. R. AU - Monk, B. J. AU - Herrstedt, J. PY - 2016 DA - 2016// TI - Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer JO - N Engl J Med VL - 375 UR - https://doi.org/10.1056/NEJMoa1611310 DO - 10.1056/NEJMoa1611310 ID - Mirza2016 ER - TY - JOUR AU - Ethier, J. L. AU - Lheureux, S. AU - Oza, A. M. PY - 2018 DA - 2018// TI - The role of niraparib for the treatment of ovarian cancer JO - Future Oncol. VL - 14 UR - https://doi.org/10.2217/fon-2018-0101 DO - 10.2217/fon-2018-0101 ID - Ethier2018 ER - TY - JOUR AU - Litton, J. K. AU - Rugo, H. S. AU - Ettl, J. PY - 2018 DA - 2018// TI - Talazoparib in patients with advanced breast cancer and a germline BRCA mutation JO - N Engl J Med VL - 379 UR - https://doi.org/10.1056/NEJMoa1802905 DO - 10.1056/NEJMoa1802905 ID - Litton2018 ER - TY - JOUR AU - McCann, K. E. PY - 2019 DA - 2019// TI - Advances in the use of PARP inhibitors for BRCA1/2-associated breast cancer: talazoparib JO - Future Oncol. VL - 15 UR - https://doi.org/10.2217/fon-2018-0751 DO - 10.2217/fon-2018-0751 ID - McCann2019 ER - TY - JOUR AU - Lowery, M. A. AU - Kelsen, D. P. AU - Capanu, M. PY - 2018 DA - 2018// TI - Phase II trial of veliparib in patients with previously treated BRCA-mutated pancreas ductal adenocarcinoma JO - Eur J Cancer VL - 89 UR - https://doi.org/10.1016/j.ejca.2017.11.004 DO - 10.1016/j.ejca.2017.11.004 ID - Lowery2018 ER - TY - JOUR AU - Gojo, I. AU - Beumer, J. H. AU - Pratz, K. W. PY - 2017 DA - 2017// TI - A phase 1 study of the PARP inhibitor veliparib in combination with temozolomide in acute myeloid leukemia JO - Clin Cancer Res VL - 23 UR - https://doi.org/10.1158/1078-0432.CCR-16-0984 DO - 10.1158/1078-0432.CCR-16-0984 ID - Gojo2017 ER - TY - JOUR AU - Rodler, E. T. AU - Kurland, B. F. AU - Griffin, M. PY - 2016 DA - 2016// TI - Phase I study of veliparib (ABT-888) combined with cisplatin and vinorelbine in advanced triple-negative breast cancer and/or BRCA mutation-associated breast cancer JO - Clin Cancer Res VL - 22 UR - https://doi.org/10.1158/1078-0432.CCR-15-2137 DO - 10.1158/1078-0432.CCR-15-2137 ID - Rodler2016 ER - TY - JOUR AU - Gabrielson, A. AU - Tesfaye, A. A. AU - Marshall, J. L. PY - 2015 DA - 2015// TI - Phase II study of temozolomide and veliparib combination therapy for sorafenib-refractory advanced hepatocellular carcinoma JO - Cancer Chemother Pharmacol VL - 76 UR - https://doi.org/10.1007/s00280-015-2852-2 DO - 10.1007/s00280-015-2852-2 ID - Gabrielson2015 ER - TY - JOUR AU - Gray, H. J. AU - Bell-McGuinn, K. AU - Fleming, G. F. PY - 2018 DA - 2018// TI - Phase I combination study of the PARP inhibitor veliparib plus carboplatin and gemcitabine in patients with advanced ovarian cancer and other solid malignancies JO - Gynecol Oncol VL - 148 UR - https://doi.org/10.1016/j.ygyno.2017.12.029 DO - 10.1016/j.ygyno.2017.12.029 ID - Gray2018 ER - TY - JOUR AU - Rugo, H. S. AU - Olopade, O. I. AU - DeMichele, A. PY - 2016 DA - 2016// TI - Adaptive randomization of veliparib-carboplatin treatment in breast cancer JO - N Engl J Med VL - 375 UR - https://doi.org/10.1056/NEJMoa1513749 DO - 10.1056/NEJMoa1513749 ID - Rugo2016 ER - TY - JOUR AU - Loibl, S. AU - O’Shaughnessy, J. AU - Untch, M. PY - 2018 DA - 2018// TI - Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial JO - Lancet Oncol. VL - 19 UR - https://doi.org/10.1016/S1470-2045(18)30111-6 DO - 10.1016/S1470-2045(18)30111-6 ID - Loibl2018 ER - TY - JOUR AU - Lord, C. J. AU - Ashworth, A. PY - 2016 DA - 2016// TI - BRCAness revisited JO - Nat Rev Cancer VL - 16 UR - https://doi.org/10.1038/nrc.2015.21 DO - 10.1038/nrc.2015.21 ID - Lord2016 ER - TY - JOUR AU - Timms, K. M. AU - Abkevich, V. AU - Hughes, E. PY - 2014 DA - 2014// TI - Association of BRCA1/2 defects with genomic scores predictive of DNA damage repair deficiency among breast cancer subtypes JO - Breast Cancer Res VL - 16 UR - https://doi.org/10.1186/s13058-014-0475-x DO - 10.1186/s13058-014-0475-x ID - Timms2014 ER - TY - JOUR AU - Turner, N. AU - Tutt, A. AU - Ashworth, A. PY - 2004 DA - 2004// TI - Hallmarks of ‘BRCAness’ in sporadic cancers JO - Nat Rev Cancer VL - 4 UR - https://doi.org/10.1038/nrc1457 DO - 10.1038/nrc1457 ID - Turner2004 ER - TY - JOUR AU - McCabe, N. AU - Turner, N. C. AU - Lord, C. J. PY - 2006 DA - 2006// TI - Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition JO - Cancer Res VL - 66 UR - https://doi.org/10.1158/0008-5472.CAN-06-0140 DO - 10.1158/0008-5472.CAN-06-0140 ID - McCabe2006 ER - TY - JOUR AU - Watkins, J. A. AU - Irshad, S. AU - Grigoriadis, A. AU - Tutt, A. N. PY - 2014 DA - 2014// TI - Genomic scars as biomarkers of homologous recombination deficiency and drug response in breast and ovarian cancers JO - Breast Cancer Res VL - 16 UR - https://doi.org/10.1186/bcr3670 DO - 10.1186/bcr3670 ID - Watkins2014 ER - TY - JOUR AU - George, J. AU - Lim, J. S. AU - Jang, S. J. PY - 2015 DA - 2015// TI - Comprehensive genomic profiles of small cell lung cancer JO - Nature VL - 524 UR - https://doi.org/10.1038/nature14664 DO - 10.1038/nature14664 ID - George2015 ER - TY - JOUR AU - Byers, L. A. AU - Wang, J. AU - Nilsson, M. B. PY - 2012 DA - 2012// TI - Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1 JO - Cancer Discov VL - 2 UR - https://doi.org/10.1158/2159-8290.CD-12-0112 DO - 10.1158/2159-8290.CD-12-0112 ID - Byers2012 ER - TY - JOUR AU - Shao, N. AU - Shi, Y. AU - Yu, L. PY - 2019 DA - 2019// TI - Prospect for Application of PARP Inhibitor in Patients with HER2 Negative Breast Cancer JO - Int J Biol Sci. VL - 15 UR - https://doi.org/10.7150/ijbs.30721 DO - 10.7150/ijbs.30721 ID - Shao2019 ER - TY - JOUR AU - Lu, Y. AU - Liu, Y. AU - Pang, Y. AU - Pacak, K. AU - Yang, C. PY - 2018 DA - 2018// TI - Double-barreled gun: combination of PARP inhibitor with conventional chemotherapy JO - Pharmacol Ther VL - 188 UR - https://doi.org/10.1016/j.pharmthera.2018.03.006 DO - 10.1016/j.pharmthera.2018.03.006 ID - Lu2018 ER - TY - JOUR AU - Cheng, C. L. AU - Johnson, S. P. AU - Keir, S. T. PY - 2005 DA - 2005// TI - Poly(ADP-ribose) polymerase-1 inhibition reverses temozolomide resistance in a DNA mismatch repair-deficient malignant glioma xenograft JO - Mol Cancer Ther VL - 4 UR - https://doi.org/10.1158/1535-7163.MCT-05-0128 DO - 10.1158/1535-7163.MCT-05-0128 ID - Cheng2005 ER - TY - JOUR AU - Tentori, L. AU - Leonetti, C. AU - Scarsella, M. PY - 2002 DA - 2002// TI - Combined treatment with temozolomide and poly(ADP-ribose) polymerase inhibitor enhances survival of mice bearing hematologic malignancy at the central nervous system site JO - Blood VL - 99 UR - https://doi.org/10.1182/blood.V99.6.2241 DO - 10.1182/blood.V99.6.2241 ID - Tentori2002 ER - TY - JOUR AU - Smith, M. A. AU - Reynolds, C. P. AU - Kang, M. H. PY - 2015 DA - 2015// TI - Synergistic activity of PARP inhibition by talazoparib (BMN 673) with temozolomide in pediatric cancer models in the pediatric preclinical testing program JO - Clin Cancer Res VL - 21 UR - https://doi.org/10.1158/1078-0432.CCR-14-2572 DO - 10.1158/1078-0432.CCR-14-2572 ID - Smith2015 ER - TY - JOUR AU - Gupta, S. K. AU - Kizilbash, S. H. AU - Carlson, B. L. PY - 2016 DA - 2016// TI - Delineation of MGMT hypermethylation as a biomarker for veliparib-mediated temozolomide-sensitizing therapy of glioblastoma JO - J Natl Cancer Inst UR - https://doi.org/10.1093/jnci/djv369 DO - 10.1093/jnci/djv369 ID - Gupta2016 ER - TY - JOUR AU - Schreck, K. C. AU - Grossman, S. A. PY - 2018 DA - 2018// TI - Role of temozolomide in the treatment of cancers involving the central nervous system JO - Oncology VL - 32 ID - Schreck2018 ER - TY - JOUR AU - Sarkaria, J. N. AU - Kitange, G. J. AU - James, C. D. PY - 2008 DA - 2008// TI - Mechanisms of chemoresistance to alkylating agents in malignant glioma JO - Clin Cancer Res VL - 14 UR - https://doi.org/10.1158/1078-0432.CCR-07-1719 DO - 10.1158/1078-0432.CCR-07-1719 ID - Sarkaria2008 ER - TY - JOUR AU - Hussain, M. AU - Carducci, M. A. AU - Slovin, S. PY - 2014 DA - 2014// TI - Targeting DNA repair with combination veliparib (ABT-888) and temozolomide in patients with metastatic castration-resistant prostate cancer JO - Invest New Drugs VL - 32 UR - https://doi.org/10.1007/s10637-014-0099-0 DO - 10.1007/s10637-014-0099-0 ID - Hussain2014 ER - TY - JOUR AU - Lesueur, P. AU - Lequesne, J. AU - Grellard, J. M. PY - 2019 DA - 2019// TI - Phase I/IIa study of concomitant radiotherapy with olaparib and temozolomide in unresectable or partially resectable glioblastoma: OLA-TMZ-RTE-01 trial protocol JO - BMC Cancer. VL - 19 UR - https://doi.org/10.1186/s12885-019-5413-y DO - 10.1186/s12885-019-5413-y ID - Lesueur2019 ER - TY - JOUR AU - Lazarevic, T. AU - Rilak, A. AU - Bugarcic, Z. D. PY - 2017 DA - 2017// TI - Platinum, palladium, gold and ruthenium complexes as anticancer agents: current clinical uses, cytotoxicity studies and future perspectives JO - Eur J Med Chem VL - 142 UR - https://doi.org/10.1016/j.ejmech.2017.04.007 DO - 10.1016/j.ejmech.2017.04.007 ID - Lazarevic2017 ER - TY - JOUR AU - Nguewa, P. A. AU - Fuertes, M. A. AU - Cepeda, V. PY - 2006 DA - 2006// TI - Poly(ADP-ribose) polymerase-1 inhibitor 3-aminobenzamide enhances apoptosis induction by platinum complexes in cisplatin-resistant tumor cells JO - Med Chem VL - 2 UR - https://doi.org/10.2174/157340606775197697 DO - 10.2174/157340606775197697 ID - Nguewa2006 ER - TY - JOUR AU - Cheng, H. AU - Zhang, Z. AU - Borczuk, A. PY - 2013 DA - 2013// TI - PARP inhibition selectively increases sensitivity to cisplatin in ERCC1-low non-small cell lung cancer cells JO - Carcinogenesis VL - 34 UR - https://doi.org/10.1093/carcin/bgs393 DO - 10.1093/carcin/bgs393 ID - Cheng2013 ER - TY - JOUR AU - Oza, A. M. AU - Cibula, D. AU - Benzaquen, A. O. PY - 2015 DA - 2015// TI - Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial JO - Lancet Oncol. VL - 16 UR - https://doi.org/10.1016/S1470-2045(14)71135-0 DO - 10.1016/S1470-2045(14)71135-0 ID - Oza2015 ER - TY - JOUR AU - Gunderson, C. C. AU - Moore, K. N. PY - 2015 DA - 2015// TI - PARP inhibition in ovarian cancer: state of the science JO - Gynecol Oncol VL - 136 UR - https://doi.org/10.1016/j.ygyno.2014.12.009 DO - 10.1016/j.ygyno.2014.12.009 ID - Gunderson2015 ER - TY - JOUR AU - Yi, M. AU - Yu, S. AU - Qin, S. PY - 2018 DA - 2018// TI - Gut microbiome modulates efficacy of immune checkpoint inhibitors JO - J Hematol Oncol. VL - 11 UR - https://doi.org/10.1186/s13045-018-0592-6 DO - 10.1186/s13045-018-0592-6 ID - Yi2018 ER - TY - JOUR AU - Yi, M. AU - Jiao, D. AU - Xu, H. PY - 2018 DA - 2018// TI - Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors JO - Mol Cancer. VL - 17 UR - https://doi.org/10.1186/s12943-018-0864-3 DO - 10.1186/s12943-018-0864-3 ID - Yi2018 ER - TY - JOUR AU - Long, J. AU - Lin, J. AU - Wang, A. PY - 2017 DA - 2017// TI - PD-1/PD-L blockade in gastrointestinal cancers: lessons learned and the road toward precision immunotherapy JO - J Hematol Oncol. VL - 10 UR - https://doi.org/10.1186/s13045-017-0511-2 DO - 10.1186/s13045-017-0511-2 ID - Long2017 ER - TY - JOUR AU - Bardhan, K. AU - Anagnostou, T. AU - Boussiotis, V. A. PY - 2016 DA - 2016// TI - The PD1:PD-L1/2 pathway from discovery to clinical implementation JO - Front Immunol. VL - 7 UR - https://doi.org/10.3389/fimmu.2016.00550 DO - 10.3389/fimmu.2016.00550 ID - Bardhan2016 ER - TY - JOUR AU - Ok, C. Y. AU - Young, K. H. PY - 2017 DA - 2017// TI - Checkpoint inhibitors in hematological malignancies JO - J Hematol Oncol. VL - 10 UR - https://doi.org/10.1186/s13045-017-0474-3 DO - 10.1186/s13045-017-0474-3 ID - Ok2017 ER - TY - JOUR AU - Yang, J. AU - Hu, L. PY - 2019 DA - 2019// TI - Immunomodulators targeting the PD-1/PD-L1 protein-protein interaction: from antibodies to small molecules JO - Med Res Rev VL - 39 UR - https://doi.org/10.1002/med.21530 DO - 10.1002/med.21530 ID - Yang2019 ER - TY - JOUR AU - Li, X. AU - Shao, C. AU - Shi, Y. AU - Han, W. PY - 2018 DA - 2018// TI - Lessons learned from the blockade of immune checkpoints in cancer immunotherapy JO - J Hematol Oncol. VL - 11 UR - https://doi.org/10.1186/s13045-018-0578-4 DO - 10.1186/s13045-018-0578-4 ID - Li2018 ER - TY - JOUR AU - Yi, M. AU - Jiao, D. AU - Qin, S. PY - 2019 DA - 2019// TI - Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment JO - Mol Cancer. VL - 18 UR - https://doi.org/10.1186/s12943-019-0974-6 DO - 10.1186/s12943-019-0974-6 ID - Yi2019 ER - TY - JOUR AU - Stewart, R. A. AU - Pilie, P. G. AU - Yap, T. A. PY - 2018 DA - 2018// TI - Development of PARP and immune-checkpoint inhibitor combinations JO - Cancer Res VL - 78 UR - https://doi.org/10.1158/0008-5472.CAN-18-2652 DO - 10.1158/0008-5472.CAN-18-2652 ID - Stewart2018 ER - TY - JOUR AU - Sen, T. AU - Rodriguez, B. L. AU - Chen, L. PY - 2019 DA - 2019// TI - Targeting DNA Damage response promotes antitumor immunity through STING-mediated T-cell activation in small cell lung cancer JO - Cancer Discov VL - 9 UR - https://doi.org/10.1158/2159-8290.CD-18-1020 DO - 10.1158/2159-8290.CD-18-1020 ID - Sen2019 ER - TY - JOUR AU - Zitvogel, L. AU - Galluzzi, L. AU - Kepp, O. AU - Smyth, M. J. AU - Kroemer, G. PY - 2015 DA - 2015// TI - Type I interferons in anticancer immunity JO - Nat Rev Immunol VL - 15 UR - https://doi.org/10.1038/nri3845 DO - 10.1038/nri3845 ID - Zitvogel2015 ER - TY - JOUR AU - Li, A. AU - Yi, M. AU - Qin, S. PY - 2019 DA - 2019// TI - Activating cGAS-STING pathway for the optimal effect of cancer immunotherapy JO - J Hematol Oncol. VL - 12 UR - https://doi.org/10.1186/s13045-019-0721-x DO - 10.1186/s13045-019-0721-x ID - Li2019 ER - TY - JOUR AU - Jiao, S. AU - Xia, W. AU - Yamaguchi, H. PY - 2017 DA - 2017// TI - PARP inhibitor upregulates PD-L1 expression and enhances cancer-associated immunosuppression JO - Clin Cancer Res VL - 23 UR - https://doi.org/10.1158/1078-0432.CCR-16-3215 DO - 10.1158/1078-0432.CCR-16-3215 ID - Jiao2017 ER - TY - JOUR AU - Wang, Z. AU - Sun, K. AU - Xiao, Y. PY - 2019 DA - 2019// TI - Niraparib activates interferon signaling and potentiates anti-PD-1 antibody efficacy in tumor models JO - Sci Rep. VL - 9 UR - https://doi.org/10.1038/s41598-019-38534-6 DO - 10.1038/s41598-019-38534-6 ID - Wang2019 ER - TY - JOUR AU - Karzai, F. AU - VanderWeele, D. AU - Madan, R. A. PY - 2018 DA - 2018// TI - Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations JO - J Immunother Cancer. VL - 6 UR - https://doi.org/10.1186/s40425-018-0463-2 DO - 10.1186/s40425-018-0463-2 ID - Karzai2018 ER - TY - JOUR AU - Thomas, A. AU - Vilimas, R. AU - Trindade, C. PY - 2019 DA - 2019// TI - Durvalumab in combination with olaparib in patients with relapsed small cell lung cancer: results from a phase II study JO - J Thorac Oncol. VL - 14 UR - https://doi.org/10.1016/j.jtho.2019.04.026 DO - 10.1016/j.jtho.2019.04.026 ID - Thomas2019 ER - TY - JOUR AU - Asim, M. AU - Tarish, F. AU - Zecchini, H. I. PY - 2017 DA - 2017// TI - Synthetic lethality between androgen receptor signalling and the PARP pathway in prostate cancer JO - Nat Commun. VL - 8 UR - https://doi.org/10.1038/s41467-017-00393-y DO - 10.1038/s41467-017-00393-y ID - Asim2017 ER - TY - JOUR AU - Li, L. AU - Karanika, S. AU - Yang, G. PY - 2017 DA - 2017// TI - Androgen receptor inhibitor-induced “BRCAness” and PARP inhibition are synthetically lethal for castration-resistant prostate cancer JO - Sci Signal. UR - https://doi.org/10.1126/scisignal.aam7479 DO - 10.1126/scisignal.aam7479 ID - Li2017 ER - TY - JOUR AU - Clarke, N. AU - Wiechno, P. AU - Alekseev, B. PY - 2018 DA - 2018// TI - Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial JO - Lancet Oncol. VL - 19 UR - https://doi.org/10.1016/S1470-2045(18)30365-6 DO - 10.1016/S1470-2045(18)30365-6 ID - Clarke2018 ER - TY - JOUR AU - Sun, C. AU - Fang, Y. AU - Yin, J. PY - 2017 DA - 2017// TI - Rational combination therapy with PARP and MEK inhibitors capitalizes on therapeutic liabilities in RAS mutant cancers JO - Sci Transl Med. UR - https://doi.org/10.1126/scitranslmed.aal5148 DO - 10.1126/scitranslmed.aal5148 ID - Sun2017 ER - TY - JOUR AU - Loven, J. AU - Hoke, H. A. AU - Lin, C. Y. PY - 2013 DA - 2013// TI - Selective inhibition of tumor oncogenes by disruption of super-enhancers JO - Cell VL - 153 UR - https://doi.org/10.1016/j.cell.2013.03.036 DO - 10.1016/j.cell.2013.03.036 ID - Loven2013 ER - TY - JOUR AU - Zhang, Z. AU - Ma, P. AU - Jing, Y. PY - 2016 DA - 2016// TI - BET bromodomain inhibition as a therapeutic strategy in ovarian cancer by downregulating FoxM1 JO - Theranostics. VL - 6 UR - https://doi.org/10.7150/thno.13178 DO - 10.7150/thno.13178 ID - Zhang2016 ER - TY - JOUR AU - Sun, C. AU - Yin, J. AU - Fang, Y. PY - 2018 DA - 2018// TI - BRD4 inhibition is synthetic lethal with PARP inhibitors through the induction of homologous recombination deficiency JO - Cancer Cell VL - 33 ID - Sun2018 ER - TY - JOUR AU - Chen, X. AU - Huan, X. AU - Liu, Q. PY - 2018 DA - 2018// TI - Design and synthesis of 2-(4,5,6,7-tetrahydrothienopyridin-2-yl)-benzoimidazole carboxamides as novel orally efficacious Poly(ADP-ribose)polymerase (PARP) inhibitors JO - Eur J Med Chem VL - 145 UR - https://doi.org/10.1016/j.ejmech.2018.01.018 DO - 10.1016/j.ejmech.2018.01.018 ID - Chen2018 ER -